US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% SKHY $195.02 ▲+0.00% SNDK $1,704.16 ▲+0.00% TSLA $378.73 ▲+0.00% INTC $116.19 ▲+0.00% AVGO $362.51 ▲+0.00%
FinancialContent

Articles published by Vor Biopharma

< Previous 1 2 3 Next >
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio To Participate in Upcoming September Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Appoints David Zaccardelli to Board of Directors
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Announces $75 Million Private Placement with TCGX
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Announces $150 Million Private Placement
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
News headline image
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
< Previous 1 2 3 Next >